|
|
Videx (Didanosine, ddI)
| Brand Name: |
Videx EC |
| Generic Name: |
Didanosine, ddI |
| Adult Single Dose: |
Patients weighing at least 133 lbs
(60 kg): one 400-mg capsule (once a day)
Patients weighing less than 133 lbs (60 kg): one 250-mg capsule (once a day) |
| Food & Liquid Restrictions: |
Take on an empty stomach,
at least 30 minutes before or two hours after eating or drinking, except
water. Do not take Videx EC with food. |
| Drug Class: |
NRTI |
The Basics
- An Overview of Videx (Didanosine, ddI) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health
- Videx and Videx EC (Didanosine, ddI) (January/February 2008)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
- Didanosine (Videx, ddI) (November 7, 2007)
To read PDF, click here
From AIDS InfoNet
- Videx EC (Didanosine, ddI EC) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
- Patient Information About Videx (Didanosine, ddI) (PDF) (March 2007)
From Bristol-Myers Squibb Company
- ddI (Videx, didanosine) (August 15, 2006)
From AIDS Treatment Data Network
- Videx (Didanosine) (May 2005)
To read PDF, click here
From The Center for AIDS
- Drug Interactions: Didanosine (August 2004)
From Project Inform
- New ddI Warning (October 2000)
In What's New, from Project Inform
- Twice-Daily ddI Recommended (Autumn 2000)
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- ddI, d4T and Hydroxyurea Side Effect Warning! (April 2000)
In Project Inform Perspective, from Project Inform
- Updates: Pancreatitis Warning for Videx (Spring 2000)
In STEP Perspective, from Seattle Treatment Education Project
News
- Videx EC Labeling Changes With Pediatric Dosing Information Added (September 30, 2008)
From U.S. Food and Drug Administration
- FDA Approves Generic Formulation of Didanosine (ddI) Delayed Release Capsules (December 3, 2004)
From AIDSinfo
- Warning on Two Specific 3-Drug Regimens: Viread + Videx + Either Sustiva or Viramune (November 23, 2004)
A brief comment on the recently issued warning that both regimens frequently fail.
In AIDS Treatment News, from AIDS Treatment News
- Thailand: Patients, Advocates Sue to Invalidate Videx EC Patent (October 10, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- New Safety Information for Videx (Didanosine, ddI) Used With Ribavirin (September 25, 2002)
From U.S. Food and Drug Administration
- ddI-Tenofovir Interaction Warning (PDF) (May 7, 2002)
From Bristol-Myers Squibb Company
- Drug Economy (July/August 2001)
Antiretroviral renegade fights fashion with didanosine + Hydroxyurea duo, betting his future on genetic barriers.
In TAGline, from Treatment Action Group
- New Formulation of ddI Approved (March 2001)
To read PDF, click here
In Project Inform Perspective, from Project Inform
- FDA Issues Warning About d4T and ddI During Pregnancy (January 22, 2001)
From Canadian AIDS Treatment Information Exchange
- FDA Approves Videx EC and Trizivir (November 27, 2000)
In STEP Ezine, from Seattle Treatment Education Project
- Enteric-coated ddI Approved: FDA Letter (November 3, 2000)
In AIDS Treatment News, from AIDS Treatment News
- Videx (Didanosine, ddI) Less Effective at Once-a-Day Dosing? (September 7, 2000)
In STEP Ezine, from Seattle Treatment Education Project
- Treatment Briefs: ddI: Once Daily & New Formulation (Winter 1999/2000)
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Recent News About ddI (September 1999)
In Project Inform Perspective, from Project Inform
Research
- Emtriva + Reyataz + Videx Not as Effective as Combivir + Sustiva in First-Line Therapy, Study Finds (May 28, 2008)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Abacavir, Didanosine Associated With Higher Heart Attack Risk, D:A:D Study Finds (February 5, 2008)
An interview with Jens Lundgren, M.D.
In 15th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Increased Risk of Myocardial Infarction Associated With Abacavir and ddI (February 4, 2008)
From HIV i-Base
- Position Statement by the D:A:D Steering Committee (February 4, 2008)
A discussion of the significance of a study examining the association between use of abacavir, didanosine and lamivudine and the risk of myocardial infarction.
To read PDF, click here
From D:A:D Steering Committee
- HIV JournalView: Tenofovir + Didanosine: The Downfall of a Lovely Combination (January 2006)
Part of David Wohl, M.D.'s review of the top 10 HIV research reports of 2005.
In HIV JournalView, from The Body PRO
- HIV JournalView: Study Ties Insulin Resistance to NRTIs, Not PIs (September 2005)
d4T and 3TC are associated with insulin resistance and high insulin levels; indinavir is associated only with elevated insulin levels; and no link to insulin abnormalities is found for AZT or ddI.
From The Body PRO
- ddI + Ribavirin May Cause Mitochondrial Toxicity (September 1, 2005)
In Journal of Acquired Immune Deficiency Syndromes
- ddI + Tenofovir Combination Linked to Higher Pancreatitis Risk (October 2004)
Quick recap of a report in The Lancet.
In HIV Treatment ALERTS!, from The Center for AIDS
- Micronutrient Supplement Can Improve d4T-, ddI-Related Neuropathy, Study Says (March/April 2004)
In Positively Aware, from Test Positive Aware Network
- High Rate of Virologic Failure With Once-Daily ddI/3TC/TDF (November 2003)
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Gilead Warns Against Use of Triple-NRTI Regimen 3TC, ddI, Tenofovir (October 14, 2003)
To read PDF, click here
From U.S. Food and Drug Administration
- Further Case Report of Lactic Acidosis Linked to Tenofovir/ddI (September 29, 2003)
From aidsmap.com
- A Comparison of AZT/3TC vs. d4T/ddI, Plus Efavirenz, Nevirapine or Indinavir/Ritonavir (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Adding ddI Achieves Fall in Viral Load in HAART Patients With Resistance (September 14, 2003)
From aidsmap.com
- HIV-Positive Man Dies of Kidney Failure and Lactic Acidosis Due to Tenofovir/ddI Interaction (April 8, 2003)
From aidsmap.com
- Didanosine and Tenofovir DF Drug-Drug Interaction: Assessment of Didanosine Dose Reduction (February 12, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- New Questions About an Old Combination -- ddI + d4T (January 2003)
To read PDF, click here
In Project Inform Perspective, from Project Inform
- Tenofovir DF and Didanosine EC: Investigation of Pharmacokinetic Drug-Drug and Drug-Food Interactions (November 21, 2002)
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO
- Viread-Videx EC Drug Interactions -- What's a Person to Do? (Fall 2002)
To read PDF, click here
In STEP Perspective, from Seattle Treatment Education Project
- Prospective Study of Regional Body Composition in Antiretroviral-Naive Subjects Randomized to Receive Zidovudine + Lamivudine or Didanosine + Stavudine Combined With Nelfinavir, Efavirenz or Both: A5005s, a Substudy of ACTG 384 (September 25, 2002)
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO
- Tenofovir DF and Didanosine EC: Investigation of Pharmacokinetic Drug-Drug and Drug-Food Interactions (July 11, 2002)
In The XIV International AIDS Conference, from The Body PRO
- Resistance Profiles at Baseline and Following Virologic Failure for Subjects Randomized to Receive Abacavir/Efavirenz/Didanosine +/-; Hydroxyurea After Failing Initial NRTI +/- PI Therapy (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO
- Hydroxychloroquine, Hydroxycarbamide, and Didanosine as Economic Treatment for HIV-1 (May 23, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Pancreatitis: An Emerging Complication of HCV Treatment in HIV Co-Infected Patients Treated With Didanosine/Stavudine Containing Regimens (December 17, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Effect of Food on Oral Bioavailability of Didanosine From Delayed Release Capsules Containing Enteric Coated Beads (December 16, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Long-Term Follow-Up of Antiretroviral-Naive HIV-Infected Patients Treated with d4T and ddI (QD) and Nevirapine (BID or QD) in the VIRGO Study (October 29, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
- ddI Warning (March 2001)
In What's New, from Project Inform
- Comparison of a Triple Combination Regimen Containing an Enteric-Coated Formulation of Didanosine Administered Once Daily Versus a Regimen of Combivir Plus Nelfinavir (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Once-Daily Combination Therapy with Emtricitabine, Didanosine, and Efavirenz in Treatment-Naive HIV-Infected Adults: 64-Week Follow-Up of the ANRS 091 Trial (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Viral Resistance Results From the International, Multicenter, Randomized, Placebo-Controlled, 48-Week Study of Hydroxyurea or Placebo Combined With Efavirenz, Didanosine and Stavudine in Treatment-Naive and -Experienced Patients (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Control of Viremia After Treatment Interruption (January 31, 2000)
In The 7th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Efavirenz (EFV) in Combination With Stavudine (d4T) and Didanosine (ddI) or Lamivudine (3TC) Is Well-Tolerated and Efficacious in the Majority of Patients Treated (October 25, 1999)
In The 7th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
- Improved Tolerability and Adherence With Reduced Mass Didanosine Tablets in HIV-1 Infected Adults Receiving Highly Active Antiretroviral Therapy (October 1999)
In The 7th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
- Efficacy of Efavirenz in Combination With Stavudine (d4T) and Didanosine (ddI) in Antiretroviral Therapy-Naïve HIV-Infected Patients (Study 044) (September 28, 1999)
In The 39th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Journal Watch: Once Daily ddI as Effective as Twice Daily (July/August 1999)
In GMHC Treatment Issues, from Gay Men's Health Crisis
- A Randomized Double-Blind Study of d4T + ddI versus ZDV + ddI as Initial Treatment in Subjects with CD4 Count <= 500 cells/mm3 (February 4, 1998)
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Antiviral Activity and Acceptance of Two Different Triple Combinations (February 3, 1998)
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- The START Trials (February 3, 1998)
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
|
|
